<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7600053</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2780</journal-id>
<journal-id journal-id-type="nlm-ta">Cancer Lett</journal-id>
<journal-id journal-id-type="iso-abbrev">Cancer Lett.</journal-id>
<journal-title-group>
<journal-title>Cancer letters</journal-title>
</journal-title-group>
<issn pub-type="ppub">0304-3835</issn>
<issn pub-type="epub">1872-7980</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31128216</article-id>
<article-id pub-id-type="pmc">6638576</article-id>
<article-id pub-id-type="doi">10.1016/j.canlet.2019.05.024</article-id>
<article-id pub-id-type="manuscript">NIHMS1530898</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Fagan</surname>
<given-names>Richard J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dingwall</surname>
<given-names>Andrew K.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60521</aff>
<aff id="A2"><label>2</label>Departments of Cancer Biology and Pathology &amp; Laboratory Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60521</aff>
<author-notes>
<fn fn-type="con" id="FN1">
<p id="P1">Author contributions</p>
<p id="P2">AD and RF conceived the idea for the review, researched the literature and wrote the manuscript.</p>
</fn>
<corresp id="CR1"><label>*</label>Correspondence: Andrew K. Dingwall, PhD, Department of Cancer Biology, Loyola University Chicago-Stritch School of Medicine, Maywood, IL, USA, 60153., <email>adingwall@luc.edu</email>, Phone: (708) 327-3141</corresp>
<fn fn-type="COI-statement" id="FN3">
<p id="P29">Conflict of interest statement:</p>
<p id="P30">The authors declare that they have no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>22</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<day>28</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>28</day>
<month>8</month>
<year>2020</year>
</pub-date>
<volume>458</volume>
<fpage>56</fpage>
<lpage>65</lpage>
<!--elocation-id from pubmed: 10.1016/j.canlet.2019.05.024-->
<abstract id="ABS1">
<p id="P3">The KMT2 (lysine methyltransferase) family of histone modifying proteins play essential roles in regulating developmental pathways, and mutations in the genes encoding these proteins have been strongly linked to many blood and solid tumor cancers. The KMT2A-D proteins are histone 3 lysine 4 (H3K4) methyltransferases embedded in large COMPASS-like complexes important for RNA Polymerase II-dependent transcription. <italic>KMT2</italic> mutations were initially associated with pediatric <underline>M</underline>ixed <underline>L</underline>ineage <underline>L</underline>eukemias (MLL) and found to be the result of rearrangements of the <italic>MLL1/KMT2A</italic> gene at 11q23. Over the past several years, large-scale tumor DNA sequencing studies have revealed the potential involvement of other KMT2 family genes, including heterozygous somatic mutations in the paralogous <italic>MLL3/KMT2C</italic> and <italic>MLL2(4)/KMT2D</italic> genes that are now among the most frequently associated with human cancer. Recent studies have provided a better understanding of the potential roles of disrupted KMT2C and KMT2D family proteins in cell growth aberrancy. These findings, together with an examination of cancer genomics databases provide new insights into the contribution of KMT2C/D proteins in epigenetic gene regulation and links to carcinogenesis.</p>
</abstract>
<kwd-group>
<kwd>Lysine methyltransferase</kwd>
<kwd>chromatin</kwd>
<kwd>epigenetic</kwd>
<kwd>co-occurrence</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>